GSK plc (LON:GSK)
United Kingdom flag United Kingdom · Delayed Price · Currency is GBP · Price in GBX
1,869.00
-60.50 (-3.14%)
Nov 17, 2026, 4:35 PM GMT
← View all transcripts

J.P. Morgan UK Leaders Conference

Nov 17, 2026

Summary

Accelerated R&D investment is supported by a GBP 1.9bn savings plan and 22 Phase III starts by year-end 2026. Launches, oncology pipeline catalysts and long-acting HIV treatments underpin the >GBP 40bn 2031 sales ambition.

Zain Ebrahim
Analyst, JPMorgan

GSK session here at the 2026 U.K. Leaders Conference. I'm Zain Ebrahim from the European Pharma team here at JP Morgan, and it's my great pleasure to welcome the CFO of GSK, Julie Brown. Julie, maybe over to you for some opening remarks.

Julie Brown
CFO, GSK

Hi. Hi, Zain. Hi, everybody. Nice to see you all on this latest slot. Just by way of opening, I'll only say a few things because I know you've got lots of questions. I think in a nutshell, we've been incredibly busy this year. We set about really, really re-energizing R&D, and we had two major work streams running in the company from the beginning. One was all about strategic portfolio management in R&D and what could we accelerate. The other work stream was all about simplifying the organization and how could we fund the growth in R&D by simplifying what we were doing day-to-day.

Those two work streams came together when we announced in July the Accelerate Growth programme, which was all about investing more in R&D, but at the same time, saving GBP 1.9 billion through the Accelerate Growth programme, the majority of which would be then invested in the assets that we'd identified for acceleration. Now we have basically, by the end of this year, 22 phase III starts, that are going to be completed by the end of this year. We're delighted with that because last year we had about seven, and the previous year we had about six. It's a multiple times acceleration.

At the same time as investing significantly in R&D, we have been able to improve the sales over the last five years by more than 8%, the profit by more than 13%, and the margin by more than 500 basis points at the same time as R&D's gone from a teen percentage of sales to basically just over 20% of sales. That's what we've been doing together with a number of acquisitions, as I mentioned, and happy to hand over to Zain for questions.

Zain Ebrahim
Analyst, JPMorgan

Perfect. That's a great introduction. This time last year we were here, and consensus for 2031 was around GBP 34.8 billion. It's now at about GBP 36.6 billion. My numbers have gone up a couple of billion as well. What do you think the market is still underappreciating as it relates to your greater than GBP 40 billion sales target for 2031? Where do you see the most upside to consensus?

Julie Brown
CFO, GSK

Yes, absolutely. The first thing to say is that when we give guidance out to 2031, we always do it on a probability of technical and regulatory success basis. This isn't a gross number. This is a net number taking the risks and the stage of development into consideration. It's usual that consensus is lower than the company. It can be quite usual because obviously the market waits for the readouts. But the biggest difference, there are small differences across the board, but the biggest difference, if I was to isolate it would be in oncology. This is largely because GSK is a smaller player in oncology. We've been building the oncology franchise.

We've now got a series of assets that could be very meaningful to the company, and there's one in particular I would highlight, which is B7-H3, which is expressed in a series of solid tumor types. We've got some incredible data readouts associated with that already from ourselves and our partner, Hansoh. In other words, we believe over the course of the next number of years, it may take two or three years, this will start to make a difference to consensus numbers together with the fact that we've got six products in the launch phase or very close to regulatory approval, which will already start to show the commercial potential of those assets. At that point, we would expect there to be moves in consensus. So consensus has moved, I think, from about GBP 33 billion to now, as you say, GBP 36.6 billion.

I make a joke to my team that I don't measure it every day, but we know the numbers to the next decimal place. I also, obviously, consensus margins out to 2030 have moved from 25% to 30%. So there has been quite a bit of movement over the last few years.

Zain Ebrahim
Analyst, JPMorgan

And you touched on the Accelerate Growth programme that you outlined with the Q2 results and the savings that it will bring to GSK in terms of GBP 1.9 billion annual savings when you get there.

Julie Brown
CFO, GSK

Yeah.

Zain Ebrahim
Analyst, JPMorgan

Can you talk through maybe how much that's going to cost you, just to remind us there, and where the savings are going to come from? Is it across both the supply chain, SG&A? How we should think about that, and how we should think about the R&D as a percentage of sales over the medium term?

Julie Brown
CFO, GSK

Okay. Yeah. So we've started the program in July, and it's progressing probably slightly ahead of schedule. It's going really well. We said GBP 1.9 billion would be achieved by 2029, 90% of which will be delivered by 2028. We're actually potentially ahead of that schedule, so already, the whole organization is geared towards delivering this in a very productive way. In terms of the major content, in terms of where it's coming from, we've put a lot of emphasis on streamlining support services. So any area of the business that is supporting what you might call the frontline, R&D, commercial activity, is looking for ways in which you can streamline. If I take some of our functions like finance, HR, legal, compliance, et cetera, they're already top quartile, but they will be even better than that as a result of this program.

The second thing we're doing is we are streamlining supply chain. Obviously, we are moving increasingly to long-acting and long-acting injectables, which means there are fewer doses going through our factories, which means we've got an opportunity to make streamlining in that area. And then we're increasingly using technology. I mean, Zain and I were talking about technology just earlier in the break. Increasingly using technology and AI to change the way we work, which gives us, again, the ability to deliver some significant savings. What we decided to do was say that the majority of the money would go towards the acceleration of R&D, because we believe that gives shareholders the best value.

However, we also appreciated that we do face a patent expiry of dolutegravir from 2028 to 2030. As a consequence of that, we decided that the margin will not just be stable through that period, but there is an opportunity for some of these savings to drop through during that period, which means the margin will be stable to improving. We will have a choice as we get closer to that as to how much we drop through and how much we retain for investment. That is the reason behind it. But yeah, very comprehensive program involving all parts of the organization. I think the reason it is energized everybody, it is not just a savings program, it is a savings program that is causing the acceleration in R&D that brings the products to patients far more quickly.

Zain Ebrahim
Analyst, JPMorgan

I definitely want to go through some of those products, but maybe to pick up on one of the elements you touched on in terms of using technology to change the way that you are working within GSK. Given how topical it is, can you maybe expand on that in terms of how is it changing the way you are thinking about SG&A? Where are you seeing the most potential for savings in those cost lines?

Julie Brown
CFO, GSK

Yeah

Zain Ebrahim
Analyst, JPMorgan

Maybe to broaden that out in terms of R&D over the medium to long term, how you are thinking about the impact it could have on R&D productivity.

Julie Brown
CFO, GSK

Yes, absolutely. It is having a potential significant benefit. The reason for that is just in the way we are working in the support functions, if you like, and in commercial. For example, the field force. I used to, at one point, lead a field force, and you would go out on rep visits with the rep to give them coaching. They did not necessarily look forward to you going with them because it is like your manager being alongside them. But with an AI coaching tool, they are delighted to get the coaching using AI because it is a lot less threatening and personal in a way, and they feel the agent is definitely on their side. So, it is changing the way they are approaching that.

The marketing mix models, we use marketing mix models to determine the responsiveness of our approach, whether it be field force, whether it be marketing, whether it be DTC. Again, we are using AI tools to be able to simulate different marketing mix scenarios and titrate accordingly. We have decided in some areas we do need feet on the ground to support some of the general medicine programs, and we have therefore brought in third parties to partner with us on some of those products. It is really changing the way we are approaching SG&A in total. I mean, the other thing it is doing in R&D, I mean, it is fundamental in R&D now in our industry.

A number of the scientists have said to me that basically they can do now before breakfast or at 3:00 A.M. in the morning when they have an idea what they used to have to wait for everybody to go back into the office to be able to do because they can use AI searching tools to be able to search targets. We use it for identifying patient populations. We use it for identifying clinical trial sites. If we are doing vaccine trials, we can identify where the virus is going to be most prevalent and site the trials in those locations. The speed at which we can operate is totally different. We are using AI and organoids to develop organs, based on tumor samples from patients. It is making a phenomenal difference in R&D. The thing that sometimes people ask me, though, is will it replace pharmaceuticals? The answer is no.

It will not replace pharmaceutical companies because who in the room, I would ask you to put your hand up, who in the room would take a pharmaceutical product that has not been tested on animals and humans and approved by the FDA if you are American? Nobody. I think you do still need the pharmaceutical industry.

Zain Ebrahim
Analyst, JPMorgan

I think that is very clear. I mean, one of the other ways with which you have accelerated along with R&D is business development. We have seen maybe the most significant deal that you have done in a number of years in the Nuvalent deal this year, which was, I think, $10.5 billion. How should we think about the pace of your deal-making going forward and your target sort of deal side, but also capacity, both from the balance sheet perspective, but also P&L perspective?

Julie Brown
CFO, GSK

Yeah. Both are very, very relevant, balance sheet and P&L. I'll start with the way we approach it and how we target it. We're looking for, I mean, we're basically very focused on two major therapeutic areas, oncology and respiratory immunology and inflammation, are the sort of broad areas we look in. We also look at vaccines, but the opportunities for BD in vaccines is more limited. What we're looking for are areas of scientifically proven mechanisms, but at the same time, where there is a clear unmet medical need. That could come through efficacy levels or it could come through tolerability levels. Nuvalent, as you raise it, Zain, is a great example of this, because Nuvalent was a precision oncology company with three assets within it. Jemperli, neladalkib, and HER2, all in the space of non-small cell lung cancer, which is a huge market.

They had identified scientifically proven mechanisms where they could totally address some tolerability issues that were there with medicines already on the market, and they could use precision oncology to make a difference to those patients. Very pleased to say that we've already now launched Jemperli. neladalkib is also coming fast on its heels, and it's due to have its PDUFA date on the 27th of November. Then we'll take them, first of all, into second line or TKI pre-treated patients, and then we'll take them a stage further into first line or TKI naive patients. So, that's the objective that we're pursuing.

Speaker 3

Yeah.

Zain Ebrahim
Analyst, JPMorgan

How should we think about the launch pace of these two drugs into the coming year? As you mentioned, their initial approval was in second line ROS cancer for Jemperli and

Julie Brown
CFO, GSK

Yeah

Zain Ebrahim
Analyst, JPMorgan

second line ALK for neladalkib. But when can we expect Jemperli to expand into first line? I think you're filing later this year. Could that help with some of the launch next year? What's the early feedback you're seeing as well for Jemperli versus maybe the competitor drug?

Julie Brown
CFO, GSK

Extremely positive feedback. I mean, one of the issues people were facing were quite serious tolerability issues with the therapies that were on the market, and therefore, the reception has been very, very positive. As you say, quite often, always in oncology, if you can move the product to first line, you unlock a considerably higher potential. Jemperli, we expect to file for the first line by the end of the year. neladalkib will be a number of years down the track in terms of first line, but the initial data is looking extremely promising. I think net-net, we will be successful with these. In terms of your question about P&L and balance sheet capacity, I should return to that. The balance sheet is healthy. We've always said strong investment grade credit rating for our balance sheet.

We're a big pharmaceutical company, and therefore, we'd expect to operate it at what you might call a reasonable level of leverage. In terms of, we're now up to 1.8x net debt to EBITDA. This is on a pro forma basis to the end of September. Last year, we were on about 1.3x. So, it's increased the leverage somewhat considerably. It still gives us space to do further deals, but we will continue to probably look in the $2 billion-$4 billion range. We're not expecting to do another neladalkib in the near future. Very importantly, though, we are very cash generative. This year, we've guided to delivering a cash generated from operations number of more than GBP 10 billion. This is at last year's exchange rates. Basically, that's what we're tracking to achieve this year.

We're cash generative, we rebuild the balance sheet, but we continue to be very active on BD. It's always really important as a company that you've got internal R&D working alongside external R&D, because you don't know where the best science is ever going to come from. It could be both. So, we pursue both. The P&L point you raised is also very important because we've got 22 phase III's running now. We've got a very active R&D machine. Tony's doing a fabulous job along with his TA heads. The P&L gets tighter. It definitely gets tighter. But then, in my experience of three big pharmaceutical companies now, it's always good when your P&L's tighter, because people are having to make harder choices, educated choices, science-based choices about new BD and the R&D that you pursue, because there's an opportunity cost associated with everything.

Zain Ebrahim
Analyst, JPMorgan

How important is that business development strategy and R&D relative to each other for that post-2031 ambition that you've outlined to Accelerate Growth, and how confident are you in that ambition? Is it dependent on some of the pipeline readouts, like the Nuvalent readout coming through? Could some of the launch assets that you have coming through in the next year help build confidence in that?

Julie Brown
CFO, GSK

Yes, I think as time goes on, as time goes on, more confidence tends to be built, to some extent internally, but even more so externally, because we have to prove that we can do it, and we have to prove especially that we can do it in oncology. So, I think confidence will build in the buy side and in the sell side as time moves on. But I think, I did extensive amount of work on this, you won't believe it, when I was in one of my former pharma companies, when I was doing the strategy role, because I looked at, do you tend to predict fairly well what the company will sell in, say, five years out? And the answer to the question was, it's fairly reliable as long as you've got a big enough portfolio. The asset split is not as reliable.

So, if you said it was going to be made up of these 20 assets and this would be the amount of each asset, it probably wouldn't be right, because things, you get puts and takes. We've taken on Nuvalent, we've launched Jemperli, we lost camlipixant about six months ago. Therefore, you're not sure which is going to win, but because you're using a probability of technical and regulatory success, you're not including the entire asset. Of those three, you're including one or two, and usually, it's overall, it's usually okay. Yeah.

Zain Ebrahim
Analyst, JPMorgan

I guess the assets launching next year that we'll be focusing on, we talked about neladalkib and Jideytro, but you'll also have Hibsago, which has been approved.

Julie Brown
CFO, GSK

Yes.

Zain Ebrahim
Analyst, JPMorgan

You've got, Exdensur, continued rollout, Blenrep continued rollout, potentially Apretude for monthly later next year.

Julie Brown
CFO, GSK

Exactly.

Zain Ebrahim
Analyst, JPMorgan

Which of these launches would you say you are most excited about and why?

Julie Brown
CFO, GSK

I am excited about, I always think, there are six products right now that are in launch phase or nearly launch phase, and I think you named the majority. Blenrep is important to us for multiple myeloma. This is a big market, even with a third-line label. This is a GBP 25 billion market moving to a GBP 43 billion market, so Blenrep. Exdensur for severe asthma is also an exciting proposition. The advantage is it is once every six months, so people only take it twice a year. The disadvantage with Exdensur is it is once every six months, and so you have got to get all the reimbursement in place before physicians will be assured of prescribing it in America because of the financial outlay. So Exdensur has now got its J code, it has got its insurance coverage.

Exdensur, we would see, start to see some of those barriers come down, and the product should perform very well. Because if you can, I mean, this is a product with 72% reduction in exacerbations that cause hospitalization. This is a major data readout. Most of the people on biologics, they drop off because they feel better. With this product, you only need two injections a year to be protected against exacerbations. It is a big, big, big innovation. So that is number two. Number three, as you said, we have got Hibsago. Those of you that do not know Hibsago, it is for hepatitis B. It is a transformational product because at the moment, there is really no functional cure for hepatitis B. This is a major problem in Japan, in China, and in the U.S.

This is a breakthrough because 19% of people with just six months therapy have the chance of a functional cure. 19% get a functional cure. There is 49% of people benefit from a reduced surface antigen level, and if you do not address hepatitis B, it leads to liver cancer and cirrhosis. So this is a transformational product. In addition to that, we have talked about neladalkib and Jideytro from the Nuvalent acquisition, both in non-small cell lung cancer. If you are looking at ROS1 and also the ALK market, do not forget that these products are taken for a long time. So these will be young people, usually non-smokers, lead very active lives, and they can take these for multiple years, and that is the difference in terms of the value of the product.

Finally, you have the HIV franchise, where we are in the process of moving to Q4M, or basically every four months, treatment and prevention. Behind it, we have every six months treatment and prevention. We are the leaders in treatment of HIV, which is 90% of the HIV market.

Zain Ebrahim
Analyst, JPMorgan

I suppose, on Exdensur, it sounds like you have the access now, but maybe just to elaborate on that in terms of how reimbursement has progressed. You have all the access you need in the U.S., and I guess there has been some patients maybe on free drugs, so how the conversion is to progressing towards paid drugs. When can we expect to sort of see that inflection come through in sales? Is that going to come through in Q4 or sometime next year? Maybe beyond the U.S., how we should think about the rollout there, because it does seem to be picking up in a few international markets.

Julie Brown
CFO, GSK

Yes.

Zain Ebrahim
Analyst, JPMorgan

Which markets have you launched in?

Julie Brown
CFO, GSK

Yes.

Zain Ebrahim
Analyst, JPMorgan

What should we think about in the next year?

Julie Brown
CFO, GSK

Yes. I think in terms of, we've now got, it's over 40 approvals for Exdensur across the world, so we are seeing some good traction building. The U.S. is usually one of the early adopting markets, and I believe, I mean, not necessarily saying it's all going to happen in the fourth quarter because all the insurance has only just been put in place, and we're now in the middle of November. But I would definitely see it coming through to some extent in the fourth quarter and then into next year, because all those reimbursement barriers that have been there for six months or so have started to be removed.

I think as long as people can get the, and physicians can get the assurance that the patient can actually pay for the product through either a scheme or however they're doing it, that removes a lot of these barriers. In terms of the market, the thing with severe asthma, only 30% of the people are being treated with biologics. That means you've got 70% of the market almost that could benefit from a treatment with biologics. These are biologic-naive patients. If they can go on a product like Exdensur with just two injections a year, and they've got a 72% reduction in exacerbations that cause hospitalization, you save the healthcare system a huge amount. You save a huge amount for the patient, including young patients. That's why I think this is such an important innovation. Yeah.

Zain Ebrahim
Analyst, JPMorgan

Hibsago is also an important innovation, as you said.

Julie Brown
CFO, GSK

Yes.

Zain Ebrahim
Analyst, JPMorgan

But it may be a more complicated launch model than.

Julie Brown
CFO, GSK

Yes

Zain Ebrahim
Analyst, JPMorgan

than we are used to.

Julie Brown
CFO, GSK

I agree.

Zain Ebrahim
Analyst, JPMorgan

In terms of how to think about the uptake, and I guess the label. There is weekly monitoring, which we need to think about. What do you see as the most appropriate analog? I think there is the hepatitis C launches from years ago. Maybe they did not have the monitoring, but they also had quite strong uptake. How should we think about that in the coming year? And maybe, how is the earlier weeks of the launch progressing?

Julie Brown
CFO, GSK

Yeah. I think in terms of we have got approval now in the U.S. and approval in Japan, and then you go through the pricing negotiations. They have gone very well, actually, in both countries. Japan gave us preferential pricing treatment. In both Japan and China, probably important to say that HepB are government priorities. And in both, I should say as well that 80% of the market is in these three countries. In China and Japan, people are tested for HepB. In fact, there is a lot of stigma associated with having HepB. It is a bit like HIV in the West. People are often tested, which means that they will be on some form of treatment, no question, probably nucleos(t)ide or, you know, but these therapies are not very effective at all.

The thing is, they will be tested, and therefore they are likely to go and be switched onto Hibsago relatively quickly in Japan and China, providing the reimbursement and the payment is in place, because there is a ready-made patient being tested already there. There are clinics already there. In the U.S. Japan, there are like 120,000 patients, for example, diagnosed and being treated. In the U.S., it is a similar number, but the total number of people in the U.S. who suffer from HepB is something like 1.7 million. There is a big gap between the number of people affected by HepB and those that are being treated. As you say, it is harder to forecast it because you do not know the chain from having the disease and going all the way down to being treated.

One thing I would say about the U.S. as well, because you think of the U.S. being a huge market, there are mostly five states where HepB is prevalent, and therefore, the commercial attention and the sell is not the whole way across America. It is really these five states. We have done a lot of analytics about how to approach the market. You started this by saying it is a difficult product to model. It is a difficult product to model, I agree. And we have got different scenarios depending on the level of penetration, and the level of uptake, and whether you get a bolus or not. I mean, these are all things that we will have to work through. But we have got our first patient in Japan.

I was talking to the head of international this morning, and they got approval, I think it was towards the end of August, and they have got the first patient in already in November. I think it was the 14th of November.

Zain Ebrahim
Analyst, JPMorgan

Should we sort of interpret that as thinking it could be somewhat steady in terms of as you build the testing in the U.S. and get that option, or if with the potential bolus, could you get sort of that HepC-like curve where you are reasonably quick to peak, and you get there maybe before 2031, where consensus has you for about GBP 1.1 billion, I think, for Hibsago?

Julie Brown
CFO, GSK

It is possible that this could go quite quickly, but I think with the U.S., because the testing isn't yet well established.

Zain Ebrahim
Analyst, JPMorgan

Yeah

Julie Brown
CFO, GSK

I think the pace may be. Different markets are going to have different dynamics. Japan, there is testing. Japan, people are being treated. That may go quite quickly. China, you've got to get over the affordability and the pricing. Then the U.S., it probably will be more of us leaning in to get the testing sorted out, a bit like we've done on some other products where you need testing alongside the therapy. In the U.S., they do need to test the blood once a week, and they are given basically a four-pack. Their first injection is by the physician. Injections two, three, and four are self-administered. We're making it as easy as possible for the patient.

Zain Ebrahim
Analyst, JPMorgan

Very clear.

Julie Brown
CFO, GSK

The physician, of course.

Zain Ebrahim
Analyst, JPMorgan

HIV, you've got about maybe 30% of the business now in long-acting.

Julie Brown
CFO, GSK

Yes

Zain Ebrahim
Analyst, JPMorgan

How is that maybe progressing relative to your expectations? I suppose with Apretude for monthly, we're trying to understand what you're seeing in terms of, I think you've got the data in-house, so what's the latest you can say there? When can we expect an update from you in terms of based on your conversation with the FDA?

Julie Brown
CFO, GSK

Yeah. I think it's probably worth saying that we've got HIV for every two months already on the market with Apretude and Cabenuva. The first of is for prevention, which is 10% of the market, and the second one is for treatment. We're now moving to every four months, Q4M, and the studies associated with Q4M are very different for prevention and for treatment. The prevention studies are PK studies, bridging study to Apretude, and the treatment study is basically an efficacy study where you're looking at the efficacy because you're dealing with people with HIV. Then the Q6M, every six months, is two different molecules altogether. I think when we did the results at Q3, people wondered if there was a read-through from the data analysis going on for Q4M prevention into the other lines, but there isn't. There isn't a connection.

We're very happy with the formulation. Obviously, what we didn't want to do when we announced the results is basically front-run the discussion with the FDA. Everybody knows in the industry, it's not a wise thing to do that. So, we wanted to make sure the first conversation about the results was with the FDA, and that's exactly what we plan to do. So, we plan to update you most probably with the full-year results.

Zain Ebrahim
Analyst, JPMorgan

It sounds like it hasn't changed your confidence, but has it changed your confidence into the Cabenuva four-monthly readout

Julie Brown
CFO, GSK

No

Zain Ebrahim
Analyst, JPMorgan

next year? How are you thinking about the pace of that launch when it comes in 2028?

Julie Brown
CFO, GSK

This, I suspect, because what we found, once we put two months out. Going back a step, the SOLAR study, 90% of people prefer long-acting injectables when they're given the choice of oral and long-acting injectables. As you say, long-acting injectables, 70% of our growth. So, people want the assurance, and they also don't want the stigma of taking tablets. This is important in HIV. They want to be able to have it via an injection. So, the move to Apretude and Cabenuva, you've seen the growth rates of being usually in the 30% range. It's quick. We've now already got 70% of our growth, 30% of our business in the U.S. We've already got a population now on Q2M. It's going to be very easy for them to move to Q4M.

As long as you've got the efficacy and the tolerability, and it looks like that is in place, then people will move. The beauty of Q4M is they're going to the sexual health clinics every four months anyway. So, they go for their test, and they can have their injection. It's a bit more tricky if they're going every two months for that. So, Q4M will make a big difference. Then, of course, Q6M is even a stage further. I would emphasize that we lead the treatment in HIV market because we have the integrase inhibitor technology, and basically 23 million out of 27 million use an integrase at the core of their treatment for HIV. So, that's why GSK is differentiated.

Zain Ebrahim
Analyst, JPMorgan

It will make sense that it will be easy to switch from Cabenuva two-monthly to Cabenuva four-monthly. When we think about taking share from the orals, dolutegravir, at least for Tivicay and TRIUMEQ, will go generic in 2028. How easy will that conversion be in terms of switching away from orals, and do you think there might be any spillover pricing that we need to think about? I think BIKTARVY also has the IRA price cut potentially implemented then, so have to think about that.

Julie Brown
CFO, GSK

Yeah. I think the market will probably be different between the U.S.A. and Europe here. The voice of the patient, the HIV patient, having spent quite a bit of time with them in the U.S., is extremely strong, and they will fight to get the best treatment. They will also, because we've done various studies that show their preference, they also prefer long-acting injectables. I think the U.S. market will benefit hugely from long-acting injectables. There are also, there's still a high incidence of new HIV infections in the U.S., so the virus is not controlled in the U.S. I think there's something like 25,000 newly infected people in the U.S. So, it's in everybody's interest to ensure they're protected.

There was a study called LATITUDE that was run at one point, basically, and the data monitoring committee stopped it early because those people on long-acting injectables were far better protected than those people on orals. There's lots of data that supports the long-acting injectable transition. When it comes to Europe, more price-sensitive, dealing with authorities that are very, very cost-conscious, as opposed to other health systems, you may get more friction going on because they may try and keep people on orals. Let's see. If they've got issues with people on orals, they're likely to move. Yeah.

Zain Ebrahim
Analyst, JPMorgan

How important is that switching really for 2031 in terms of HIV in the context of your total target? Because it's obviously quite a significant part of the business now, but as you transition more towards oncology-

Julie Brown
CFO, GSK

Yeah

Zain Ebrahim
Analyst, JPMorgan

does the ability to maybe offset some of that through the switching to long-acting, is that still quite an important part to the pillar to get to GBP 40 billion?

Julie Brown
CFO, GSK

Well, in terms of the transition, we do expect erosion in HIV from dolutegravir, no question. HIV will give itself some degree of protection for the reasons we've mentioned through LAIs. However, it won't be complete replacement. We've talked about why. GSK is building other franchises simultaneously, and as you know, we're building the specialty care franchise considerably because it's gone from a third of our business to 43% of our business, and it'll be more than 50% of the business. The idea is that oncology, respiratory immunology, inflammation, and some of the assets we've spoken about, like Mo-Rez, Ris-Rez, efimosfermin, velzatinib, all these assets are coming behind, still to be launched, still have readouts coming, and that will therefore be able to offset some of the HIV headwinds.

Zain Ebrahim
Analyst, JPMorgan

Ris-Rez, we have a phase III readout, I think late next year.

in second-line extensive small cell lung. How should we think about the uptake there? How important is it to I think you've already started the first-line trial as well. How important is the first-line opportunity to be able to make Ris-Rez a multi-blockbuster drug that could then offset some of the HIV pressure?

Julie Brown
CFO, GSK

Yeah. Ris-Rez, I am glad you have drawn attention to this one. We refer to this as a pipeline within a product. Because B7-H3 is expressed in multiple tumor types, which means it has the potential. We are first of all going into small cell lung cancer. We are going into prostate cancer, osteosarcoma. The data, the initial data from this product is phenomenal. If I just take small cell lung cancer, it is basically giving overall survival of 18.5 months. The current standard of care is 10.3 months, and the recent product from Amgen is actually 13.4 months. So you are dealing with quite a big step change in terms of overall survival. Similarly, as you mentioned, we will move. Most of these products start in second line. You then try and put them also into first line.

Gastrointestinal tumor, we have got a product here for GIST, which velzatinib, which is going into second line. It is recruiting for first line. The recruitment rate is phenomenal because people, there is a need for it. When an oncology trial recruits 50% of its patients within a short time, it is worth sitting up and looking at it. It really is. So yeah, I think we have got some good growth engines. To get more than 40 and to get beyond the 40 in 2031, we have got very strong growth prospects on the back of all these products that are now coming through development. You do not easily get to 22 phase III starts in a single year.

Zain Ebrahim
Analyst, JPMorgan

We are nearly at time, but you mentioned it is a portfolio approach, but which of the catalysts that you have got, you have got quite a few in the next 12 to 18 months, are you most excited about?

Julie Brown
CFO, GSK

Definitely excited about, it is like choosing your children. Definitely excited about Ris-Rez, most definitely. Also excited about Exdensur. Excited about the velzatinib readouts in first and second line. Very excited about the Nuvalent assets. The tolerability benefits are considerable because these are young patients, usually non-smokers, who will be on the therapy for a long time, and the current therapies cause them to put on a significant amount of weight. They often have to take GLPs, and also develop anxiety and depression, and serious psychosis in some cases. So, we are offering a real advantage to patients.

Zain Ebrahim
Analyst, JPMorgan

Perfect. I think that's a good place to close. Thanks everyone for joining, and thanks, Julie, for your time.

Julie Brown
CFO, GSK

Great. Thank you.